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Abstract 
Advances in the current knowledge of pathogenetic mechanisms of rheumatoid arthritis have 
contributed to the development of biological therapy, and translated research findings into clinical 
practice. TNF- (infliximab, etanercept, adalimumab), IL-1 (anakinra) and IL-6 (tocilizumab) 
inhibitors, a B-cell depleting agent (rituximab) and a drug blocking T-cell costimulation 
(abatacept) have been approved for rheumatoid arthritis. The progress in manufacturing 
biotechnology has contributed to the development of several other prospective agents that may 
form the basis for the therapy of rheumatoid arthritis in the near future. New or modified TNF- 
inhibitors (golimumab, certolizumab pegol), new monoclonal antibodies against other cytokines 
(e.g. IL-1, IL-6, IL-12, IL-15, IL-17, IL-23), and other agents targeting B-cell depletion (e.g. 
ocrelizumab, ofatumumab) are in various stages of development. Many pharmaceutical 
companies have focused on developing small molecule inhibitors with possible peroral 
administration, which are considered promising drugs for rheumatoid arthritis. In most cases, 
these small molecules inhibit cellular kinases (e.g. p38, JAK or Syk) that mediate the signaling 
and transcription of proinflammatory genes. In this review, we describe the cytokine inhibitors 
and modulators of the immune response currently in ongoing clinical trials, the results of which 
may further expand the spectrum of efficient therapies for chronic autoimmune diseases. 
 
Key words: rheumatoid arthritis, biological therapy, clinical trials, monoclonal antibodies, small 
molecules 
 
Take-Home messages: 
 Spectrum of monoclonal antibodies are currently tested in clinical trials including TNF- 
inhibitors (golimumab, certolizumab pegol), inhibitors of several pro-inflammatory 
cytokines such as IL-1, IL-6, IL-12, IL-15, IL-17, or IL-23, and  agents targeting B-cells 
(ocrelizumab, ofatumumab, TRU-015)  
 Small molecule inhibitors, particularly inhibitors of JAK3 and Syk kinases, are currently 
the most encouraging therapeutics for rheumatoid arthritis; however long-term efficacy 
and treatment safety have yet to be shown. 
 Treg cells, innate immune system, several new cytokine-like molecules, RNA 
interference or epigenetic alterations expand the spectrum of new promising targets for 
autoimmune disorders  
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Introduction 
Biological therapy has become a cornerstone in the treatment of rheumatoid arthritis (RA) with 
inadequate response to standard disease modifying antirheumatic drugs (DMARDs). Currently, 
seven approved biological agents are available (Table 1). Biological therapy targeting molecules 
and cells specific for processes associated with the pathogenesis of RA is very efficient yet still 
unable to induce remission or even cure in most patients. Expanding spectrum of potential 
therapies is currently being tested in various stages of clinical trials that have been facilitated by 
recent understandings regarding the pathogenesis of RA. The aim of this report is to review 
potential new therapeutic concepts, which may be promising for patients with RA. 
 
Prospective biological agents 
Pharmaceutical companies aim to modify existing agents or develop further biological 
therapeutics and treatment strategies in order to reduce the costs of manufacturing technology, as 
well as to improve the clinical efficacy and perhaps even induce total remission of the disease. 
The most promising agents currently being tested in various stages of clinical trials are 
summarized in table 2. Biological agents can be divided into monoclonal antibodies and small 
molecules (1, 2).  
 
Monoclonal antibodies 
The use of monoclonal antibody therapy in rheumatology has increased in recent years (1). 
Initially, these treatments consisted of chimeric antibodies with human constant regions of light 
and heavy chain and the variable murine binding site for the target molecule. Progress in 
manufacturing technology led to a reduction of immunogenicity, and humanized and eventually 
fully human antibodies were created. These antibodies function by neutralizing a target cytokine 
or its receptor, blocking costimulation molecules, and inducing cytolysis, apoptosis or depletion 
of target cell molecules. 
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TNF- inhibitors. Two additional TNF- blocking agents are likely to be approved in 2009 for 
the treatment of RA. Preliminary data of subcutaneously administered golimumab (CNTO148), a 
fully human monoclonal anti-TNF- antibody and certolizumab pegol (Cimzia), a humanized 
monoclonal anti-TNF- antibody exhibit the same efficacy and spectrum of adverse events as 
currently available TNF- inhibitors (3, 4).  
 
IL-1 inhibitors. To simplify the dosing, decrease the risks of local adverse events, increase the 
affinity to IL-1, and thus improve the efficacy compared to anakinra, a humanized monoclonal 
antibody targeting IL-1, canakinumab (ACZ885), has been recently developed. The preliminary 
results of clinical trials in patients with systemic juvenile idiopathic arthritis are promising (5), 
and a phase II clinical trial in patients with RA began in 2008 (http://clinicaltrials.gov). 
  
IL-6 inhibitors. Tocilizumab is a humanized monoclonal antibody against IL-6 receptor. The 
results of several phase III clinical trials suggest tocilizumab as an agent with extreme potential 
for the treatment of active RA (6). As of 2009, the European Medicines Agency (EMEA) 
described a favorable benefit-to-risk balance for tocilizumab in combination with MTX, and 
approved this indication for the treatment of moderate to severe active RA in adult patients who 
have either responded inadequately or were intolerant to previous therapy with one or more 
DMARDs or TNF- inhibitors (http://www.emea.europa.eu). In 2008, a phase II clinical trial of a 
subcutaneously administered monoclonal antibody against IL-6 (CNTO 136) was initiated to 
establish the suitable dosage, and confirm the efficacy and safety of the drug 
(http://clinicaltrials.gov). 
 
IL-15 inhibitor. Blocking IL-15 in an experimental model of arthritis led to a significant 
reduction of cartilage and bone destruction. The first open, placebo-controlled, double blind study 
 3
proved the humanized monoclonal antibody against IL-15 (HuMaxIL-15) to be efficient (7), 
however, a phase II clinical trial of a fully human monoclonal antibody against IL-15 (AMG 714) 
failed to confirm significant efficacy.  Other cytokines, such as IL-2, IL-4, IL-7, IL-9 and IL-21, 
share an identical receptor subunit of the γ chain and thus some functions of IL-15. So far, no data 
is available on the use of these cytokines as a therapeutic target in RA patients.  
 
IL-17 inhibitor. Th17 cells, a subset of memory T-cells that play a key role in an autoimmune 
inflammation, are a major source of IL-17. IL-17 increases production of several 
proinflammatory cytokines such as IL-1, IL-6, or TNF- and regulates osteoclastogenesis. 
Inhibition of IL-17 generated successful results in the treatment of an experimental arthritis 
model (8). A phase I/II clinical trial of a monoclonal antibody against IL-17 (AIN457) in patients 
with RA is currently in progress (http://clinicaltrials.gov).  
 
IL-12/IL-23 inhibitor. IL-12 is a key inducer of Th1 polarization and IL-23 is responsible for the 
proliferation of a Th17 subset of memory T-cells (9). A recent clinical trial evaluating the effect 
of a specific monoclonal antibody, ustekinumab, against the p40 subunit of cytokines IL-12 and 
IL-23 in patients with psoriasis has generated promising results (10). On an experimental level, a 
positive effect of an IL-23 blocking antibody was described in collagen-induced arthritis (11) and 
one proof-of-concept study has shown that besides associated psoriatic skin lesions, ustekinumab 
treatment can also reduce the signs and symptoms of arthritis in patients with psoriatic arthritis 
(12). Recently initiated clinical trials could show if ustekinumab is of any practical use in the 
treatment of RA (http://clinicaltrials.gov). 
 
Inhibitors of the TNF superfamily members. The results of a phase II clinical trials of 
baminercept (BG9924), an inhibitor of LT (lymphotoxin-), and belimumab, a fully human 
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monoclonal anti-BAFF (B-cell activating factor) antibody, have not been encouraging thus far in 
RA patients (http://clinicaltrials.gov). To increase the effect on B-cell maturation, atacicept, a 
recombinant fusion protein of BAFF and the APRIL (a proliferation-inducing ligand) receptor 
(TACI-Ig) was designed. Results of a phase I clinical trial shows a depletion of peripheral B-cells 
as well as decrease in rheumatoid factors (RFs) and anti-citrullinated peptide antibodies (ACPA). 
During the three-month study, a positive clinical effect was observed in a small group of patients; 
however, no significant decrease of acute phase reactants was observed (13).  
 
Inhibitors of osteoclastogenesis. A monoclonal antibody against receptor activator for nuclear 
factor B ligand (RANKL) denosumab is an efficient inhibitor of osteoclastogenesis that is in 
phase III clinical trial in patients with postmenopausal osteoporosis. Subcutaneous administration 
of denosumab every six months led to significant retardation of radiographic progression in 
patients with active RA after one year (14). The therapy was well tolerated, yet does not exhibit a 
larger effect on the disease activity.  
 
Inhibitors of chemokines and angiogenesis. On an experimental level, blocking several specific 
chemokines or their receptors has been successfully tested; however, early phases of clinical trials 
in patients with active RA have not proven a sufficient clinical effect of monoclonal antibodies 
against CCL-2/MCP-1 or its receptor CCR-2 (15, 16). Angiogenesis occurs in the early phase of 
RA and enables chemotactic migration of inflammatory cells into the synovial tissue. A 
monoclonal antibody against vascular endothelial growth factor (VEGF), bevacizumab (Avastin), 
significantly expanded therapeutic possibilities in oncology (17). A preclinical trial recently 
demonstrated a prophylactic effect of a VEGF beta monoclonal antibody in a murine model of 
arthritis; however, there has been no significant impact on an established disease (18).  
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Regulators of apoptosis. In general, cells from RA synovial tissue are resistant to apoptosis, and 
activated synovial fibroblasts and/or other joint tissue resident cells may presumably escape the 
effect of the current biological therapies (Fig. 1). Over 10 years ago, a strategy for treatment of 
RA that induced apoptosis by binding the FAS receptor had been introduced in an in vivo model 
of arthritis (19). The first monoclonal anti-FAS IgM antibody (ARG098) was subsequently 
developed, and is being tested as a single intraarticular application into an active knee in a phase I 
clinical trial in patients with RA (http://clinicaltrials.gov).  
 
T-cell inhibitors. Clinical trials directly targeting T-cells - alemtuzumab (anti-CD52, Campath-
1H), keliximab (chimeric monoclonal anti-CD4 antibody) or clenoliximab (the IgG4 version of 
the previous antibody) were accompanied by serious adverse events linked with severe CD4+ T-
lymphocytopenia and a rash, leading to discontinuation of the clinical trials of these agents (20). 
The improved knowledge of the co-stimulation regulatory mechanisms and good efficacy and 
safety profile in clinical trials facilitated recently abatacept approval for the treatment of RA (21).  
 
B-cell inhibitors. Progress in manufacturing technology led to the development of ocrelizumab, a 
humanized monoclonal antibody, and ofatumumab (HuMax-CD20), a fully human monoclonal 
antibody against CD20, which are in phase III clinical trials (22, 23). The results of early phases 
of studies show a good effect of both agents in patients refractory to both methotrexate and TNF-
 inhibitors. Compared to rituximab, minimum immunogenicity was observed. A phase I clinical 
trial of a fully human monoclonal anti-CD19 antibody (MDX-1342) is currently in progress in 
patients with active RA (http://clinicaltrials.gov). Trubion Pharmaceuticals developed SMIP 
(small modular immunopharmaceutical), which binds and specifically blocks the CD20 molecule 
(TRU-015) and induces a peripheral B-cell depletion (http://www.trubion.com). A phase II 
clinical trial is currently in progress (http://clinicaltrials.gov), and results should indicate potential 
advantages of this agent in comparison with other therapeutics targeting B-cells. As this molecule 
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is smaller than a standard monoclonal antibody, it is thought to have better tissue penetration, 
efficacy and safety profile. 
 
Small molecules 
More than half of the new anti-inflammatory therapies in preclinical and clinical trials involve 
small molecules, the molecular weights of which do not exceed 1kDa (2). These agents are 
available for peroral administration, should be less expensive; furthermore should have at least 
the same efficacy as the current biological therapy, and a reduced risk of adverse events. Recently 
developed small molecules have a targeted impact on various intercellular factors or cell 
structures, including receptors, intracellular signaling pathways and enzymes participating in the 
pathogenesis of RA. 
 
Inhibitors of intracellular signaling molecules 
Binding of an extracellular factor (e.g. a cytokine or a pathogen) to a cell-surface receptor 
activates cytoplasmic kinases: mitogen-activated protein kinases (p38, ERK, JNK) or tyrosin 
kinases (JAK, Syk), which can subsequently modulate the activity of transcription factors, thus 
regulating the expression of target genes (Fig. 2). Perorally administered drugs that modify the 
regulation of complex intracellular signaling pathways have been tested with a variable clinical 
response. 
 
Inhibitors of MAP kinase p38. Based on very promising preclinical data, a number of 
pharmaceutical companies have developed inhibitors of MAP kinase p38 that predominantly 
impact its alpha subunit. Most of the therapeutics are in phase II clinical trials; the therapeutic 
effects have not yet reached expectations. Moreover, the latest data has shown that pamapimod 
was even less effective than MTX in patients with active RA (24). Based on these data, one can 
speculate that other signaling pathways are predominantly involved in the pathogenesis of RA.  
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Inhibitors of the JAK/STAT signaling pathway. Tyrosine Janus kinases (JAK) can be activated 
by interferon- and other cytokines playing a significant role in the pathogenesis of RA (25). 
Pfizer developed a JAK3 inhibitor (CP-690,550), which has already been in a phase II clinical 
trial in patients with moderately- to severely-active RA (26). The results of this study have been 
very encouraging so far; after 12 months of administration, remission was achieved in 
approximately one-third of the individuals, and a relatively good tolerance and safety profile of 
the therapy was observed. A multicentre study is currently in progress comparing the effect of 
five dosing regimens of JAK-3 inhibitor with TNF inhibitor (adalimumab) and DMARDs in 
patients with active RA (http://clinicaltrials.gov).  
Inhibitors of Syk kinase. Intracellular Spleen tyrosine kinase (Syk) has significant 
immunomodulatory activity, and is stimulated by activation of Fc receptors and B-cell receptors. 
This signaling pathway is upstream MAP-kinases, especially JNK, and its activation plays a key 
role in the TNF- induced expression of proinflammatory cytokines and proteolytic enzymes by 
synovial fibroblasts (27). Use of a Syk kinase inhibitor (Fostamatinib disodium) has produced 
very good results with regard to attenuation of clinical activity of RA (28). After 12 weeks of 
peroral administration of 150 mg of the agent twice a day, remission was observed in almost half 
of the individuals. Nevertheless, the prevalence of adverse events (e.g. diarrhea, increased blood 
pressure, neutropenia and elevation of liver enzymes) increased due to this relatively high dosage.  
Inhibitors of transcription factors. The NFB (nuclear factor B), NFAT (nuclear factor for 
activation of T-cells) and AP-1 (activator protein) transcription factors have been shown to play 
the most critical roles in the pathogenesis of RA. The first preclinical data from an experimental 
model of arthritis have shown that treatment with c-Fos/AP-1 inhibitor (T-5224) prevents 
synovitis, osteoclastogenesis, and the subsequent destruction of a joint (29). I kinases (IKK)-2 
has been shown to play a central role in regulating NFB signaling and a highly selective IKK-2 
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inhibitor has been very recently introduced to inhibit the expression of various inflammatory 
mediators as well as to block joint swelling and bone destruction in an experimental model of 
arthritis (30). Another approach to inhibit NFB, permeable NBD peptide, has been demonstrated 
through blocking the regulatory activity of NFB. Its intraarticular administration into a rat joint 
with adjuvant arthritis led to significant attenuation of synovitis and joint destruction (31). 
Inhibitors of cytokines and chemokines 
Synta Pharmaceuticals has developed a small molecule IL-12/IL-23 inhibitor (Apilimod 
mesylate), which, based on clinical results, is presumed to have an impact on immune response 
showing decrease of several proinflammatory cytokines and a retardation of RA progression. This 
drug has been successfully tested in patients with Crohn’s disease, and a phase II clinical trial in 
patients with RA is currently in progress (32). A selective antagonist of a chemokine receptor 
CCR5, maraviroc, was well tolerated, without severe adverse events; however, due to lack of 
efficacy, the phase II clinical trial in patients with RA was terminated at the end of 2008. 
Inhibitors of cell surface markers 
RhuDex, a small molecule blocking the CD80 marker on antigen presenting cells, is one of the 
first modulators of T-cell costimulation available in peroral administration. A phase I clinical trial 
was already in progress, and 80 patients have been enrolled in this study so far; however, it was 
discontinued in July 2008 due to death of one volunteer from myocardial infarction. The 
pharmaceutical company was requested to complete in vitro tests to exclude possible drug 
interactions supporting atherogenesis (http://www.medigene.com).  
 
Conclusions 
A growing knowledge of the pathogenesis of an autoimmune inflammatory process has expanded 
the spectrum of new molecules and some of these may become the therapeutic targets of RA (33). 
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The therapeutic possibilities have been expanded by new monoclonal antibodies against several 
proinflammatory cytokines, chemokines, growth factors, cytokine and chemokine receptors, or 
agents targeting cell surface markers. Most encouraging therapeutic strategies of recent years are 
small molecules; mostly inhibitors of intracellular signaling pathways. These have the advantage 
of peroral administration. Since intracellular signaling pathways have pleiotropic effects, focusing 
on the efficacy and especially the long term safety in further studies will be needed.   
 
There are many other targets with potential therapeutic utility approaching for example regulatory 
T cells (Treg) (34), Toll like receptors (35), complement pathway mediated by C5a (36) or 
adipokines – e.g. visfatin/PBEF (37). The future of biological therapy may also develop 
according to new scientific advancements in genetic engineering, possibilities of affecting gene 
transcription using RNA interference with small interfering RNA or microRNA as well as 
possibilities of epigenetic alterations (DNA methylation and histone modifications), which may 
affect the regulation of inflammation and autoimmune process during the course of rheumatic 
disorders (38, 39). In this regard it needs to be stressed that no therapy has been targeting so far 
the epigenetically activated synovial fibroblast operating the cytokine independent pathway of 
RA (39, 40). 
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Tables 
 
Table 1.  Currently used biological therapies for rheumatoid arthritis. 
____________________________________________________________________________ 
TNF- inhibitors 
Infliximab (Remicade) - chimeric monoclonal antibody 
Etanercept (Enbrel) - TNF- receptor 
Adalimumab (Humira) - human monoclonal antibody 
 
IL-1 inhibitor 
Anakinra (Kineret) - IL-1 receptor antagonist 
 
IL-6 inhibitor 
Tocilizumab (Actemra) - humanized monoclonal anti- IL-6 receptor antibody 
 
B-lymphocyte depletion 
Rituximab (MabThera) - monoclonal anti-CD20 antibody 
 
Inhibition of costimulation 
Abatacept (Orencia) - fusion protein CTLA-4 with immunoglobulin 
____________________________________________________________________________ 
TNF, tumor necrosis factor; IL, interleukin; CTLA-4, cytotoxic T-lymphocyte antigen 4. 
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Table 2. Perspective biological therapies for rheumatoid arthritis in clinical trials 
 
Therapeutic aim/drug    Phase of clinical trial 
____________________________________________________________________________ 
Novel TNF- inhibitors 
Golimumab - fully human monoclonal antibody, under regulatory review 
Certolizumab pegol (Cimzia) - humanized monoclonal antibody, under regulatory review 
 
Novel IL-1 inhibitors    
Canakinumab (ACZ885), humanized monoclonal antibody against IL-1  II 
 
Inhibitors of cytokines from the TNF superfamily 
Atacicept/TACI-Ig - recombinant fusion protein of BAFF- and APRIL-receptor II 
 
Inhibitors of other cytokines 
HuMaxIL-15 - humanized monoclonal anti-IL-15 antibody    II 
AIN457 - monoclonal anti-IL-17 antibody     I/II 
 
Inhibitors of osteclastogenesis 
Denosumab - monoclonal antibody against RANKL   III 
 
Inhibitors of B-lymphocyte cell-surface markers 
Ocrelizumab - humanized monoclonal anti-CD20 antibody   III 
Ofatumumab - fully human monoclonal anti-CD20 antibody   III 
TRU-015 - small antibody polypeptide (SMIP) blocking CD20   II 
 
Small molecules 
Inhibitors of p38 kinase      II 
Inhibitor of JAK3 kinase (CP-690,550)     II 
Inhibitor of Syk kinase (Fostamatinib)     II 
IL-12/IL-23 inhibitor (Apilimod, STA-5326)     II 
Inhibitor of CD80-CD28 costimulation (RhuDex)    I 
____________________________________________________________________________ 
TNF, tumor necrosis factor; BAFF, B-cell activating factor; APRIL, a proliferation-inducing 
ligand; IL, interleukin; RANKL, receptor activator for nuclear factor B ligand; SMIP, small 
modular immunopharmaceutical; MAPK, mitogen-activated protein kinase; JAK, Janus tyrosine 
kinase; Syk, spleen tyrosine kinase. 
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Legends to figures 
 
Figure 1. Regulation of proinflammatory cytokines and immune cells within a joint by 
currently available biological therapies for rheumatoid arthritis. Therapeutical agents 
inhibiting activated synovial fibroblasts and/or other resident tissue cells are still 
unavailable, which may explain that not all patients are sufficiently responsive to current 
biological therapy. Thereby other targets, modulators of apoptosis or small molecule 
inhibitors regulating intracellular signaling pathways could be beneficial (see Fig. 2).  
 
 
 
Figure 2. Schematic drawing of signal transduction pathways and transcription factors, 
and their potential modulation by peroral inhibitors. Upon exposure of a cell to stress, 
proinflammatory environment, cytokines or pathogens, several regulatory enzymes are 
phosphorylated and activated. As a result, an intracellular signaling cascade is activated 
to transmit the signal from a receptor via MAP and tyrosine kinases to transcription 
factors, which affect the expression of genes for cytokines, matrix metalloproteinases, 
apoptosis regulating molecules, proliferation, etc. Inhibitors of Syk kinase and Jak3 have 
been most successful in clinical trials in patients with rheumatoid arthritis so far. 
 
MAPK, mitogen-activated protein kinase; MAPKK, MAPK kinase; MAPKKK, MAPKK kinase; 
JAK, Janus tyrosine kinase; STAT, signal transducer and activator of transcription; Syk, spleen 
tyrosine kinase; IKK, inhibitor IB; JNK, c-Jun N-terminal kinase; ERK, extracellular signal-
regulated kinases; NF-B, nuclear factor-B; AP1, activator protein 1; ATF2, activating 
transcription factor 2, TNF, tumor necrosis factor; IL, interleukin; MMPs, matrix 
metalloproteinases. 
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